To Our Shareholders
and Investors

• September 09, 2025

  R & D
  FDA Grants Fast Track Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis
• August 19, 2025

  R & D
  RGX-121 (clemidsogene lanparvovec) : Regarding the extension of the U.S. FDA review period
• August 12, 2025

  Management & Finance
  Notice Regarding Completion of Disposal of Treasury Stock as Restricted Stock Compensation
• August 07, 2025

  Management & Finance
  Outline of Consolidated Financial Results for the First Quarter Ended June 30, 2025

Upcoming Events

• August 07, 2025
  FY2025 1st Qtr results announcement
• August 07, 2025
  Conference Call(Q1/FY2025)
• May 08, 2025
  IR Meeting (Q4/FY2024) PDF1 MB
• May 08, 2025
  FY2024 Annual results announcement PDF1.9 MB
• February 18, 2025
  R&D Meeting PDF1.7 MB